Compare Abeona Therapeutics Inc (ABEO) vs Air Products & Chemicals, Inc. (APD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Air Products & Chemicals, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while Air Products & Chemicals, Inc. trades at $297.93 (market cap $67.93B). The key difference: Air Products & Chemicals, Inc. is far larger — about 182× Abeona Therapeutics Inc's market cap, and Air Products & Chemicals, Inc. pays a 2.37% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | APD | |
|---|---|---|
Market Cap | $373.32M | $67.93B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $314.19 |
52-Week Low | $4.17 | $230.42 |
Enterprise Value | $228.22M | $85.34B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
APD trades at $305.05, down 2.91% on the day, with a bullish technical outlook supported by moving averages and strong analyst consensus. The stock has consistently beaten earnings estimates in recent quarters, though 2025 saw a net loss of $394.50 million. Recent strategic moves include exiting the Louisiana Clean Energy Complex and finalizing a renewable ammonia deal with Yara, signaling a refined growth focus.
The outlook is positive with a consensus price target of $324.89, implying 6.5% upside. Risks include high debt levels and volatile cash flows from heavy investments. Investors should weigh the company's long-term growth projects against near-term financial pressures and geopolitical uncertainties affecting supply chains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Air Products & Chemicals, Inc.
Since its founding in 1940, Air Products has become one of the leading industrial gas suppliers globally, with operations in 50 countries and 19,000 employees. The company is the largest supplier of hydrogen and helium in the world. It has a unique portfolio serving customers in a number of industries, including chemicals, energy, healthcare, metals, and electronics. Air Products generated $10.3 billion in revenue in fiscal 2021.
Read more on APD →
